A5062251863- Multiple Myeloma Research and Treatments
- Protein Degradation and Inhibitors
- Immune cells in cancer
- Acute Myeloid Leukemia Research
- Immune Cell Function and Interaction
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Ubiquitin and proteasome pathways
- MicroRNA in disease regulation
- Cancer Mechanisms and Therapy
- RNA modifications and cancer
- Acute Lymphoblastic Leukemia research
- RNA Research and Splicing
- Cancer-related molecular mechanisms research
University Hospital Ulm
2015-2023
The bone marrow niche has a pivotal role in progression, survival, and drug resistance of multiple myeloma cells. Therefore, it is important to develop means for targeting the microenvironment. Myeloma-associated macrophages (MAM) are M2 like. They provide nurturing signals cells promote immune escape. Reprogramming M2-like toward tumoricidal M1 phenotype represents an intriguing therapeutic strategy. This especially interesting view successful use mAbs against cells, as these therapies hold...
The introduction of new drugs in the past years has substantially improved outcome multiple myeloma (MM). However, majority patients eventually relapse and become resistant to one or drugs. While genetic landscape relapsed/ been elucidated, causal relationship between relapse-specific gene mutations sensitivity a given drug MM not systematically evaluated. To determine functional impact mutations, we performed combined whole-exome sequencing (WES) longitudinal patient samples with...
Abstract BRCA1/BRCA2-containing complex 3 ( BRCC3 ) is a Lysine 63-specific deubiquitinating enzyme (DUB) involved in inflammasome activity, interferon signaling, and DNA damage repair. Recurrent mutations have been reported myelodysplastic syndromes (MDS) but not de novo AML. In one of our recent studies, we found selectively 9/191 (4.7%) cases with t(8;21)(q22;q22.1) AML 160 inv(16)(p13.1q22) Clinically, patients had an excellent outcome event-free survival 100%. Inactivation by...
Micro-ribonucleic acid-155 (miR-155) is one of the first described oncogenic miRNAs. Although multiple direct targets miR-155 have been identified, it not clear how contributes to pathogenesis acute myeloid leukemia. We found be a target Meis1 in murine Hoxa9/Meis1 induced The additional overexpression accelerated formation leukemia Hoxa9 as well cells vivo. However, absence or following removal miR-155, onset and progression were unaffected. growth homing addition impairing differentiation,...
<div>Abstract<p>The bone marrow niche has a pivotal role in progression, survival, and drug resistance of multiple myeloma cells. Therefore, it is important to develop means for targeting the microenvironment. Myeloma-associated macrophages (MAM) are M2 like. They provide nurturing signals cells promote immune escape. Reprogramming M2-like toward tumoricidal M1 phenotype represents an intriguing therapeutic strategy. This especially interesting view successful use mAbs against...
<div>Abstract<p>The bone marrow niche has a pivotal role in progression, survival, and drug resistance of multiple myeloma cells. Therefore, it is important to develop means for targeting the microenvironment. Myeloma-associated macrophages (MAM) are M2 like. They provide nurturing signals cells promote immune escape. Reprogramming M2-like toward tumoricidal M1 phenotype represents an intriguing therapeutic strategy. This especially interesting view successful use mAbs against...
<p>Supplemental Figures 1-24 and Tables 1-3</p>
<p>Supplemental Figures 1-24 and Tables 1-3</p>